A detailed history of Hcr Wealth Advisors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hcr Wealth Advisors holds 14,441 shares of BMY stock, worth $584,138. This represents 0.12% of its overall portfolio holdings.

Number of Shares
14,441
Previous 14,618 1.21%
Holding current value
$584,138
Previous $750,000 4.4%
% of portfolio
0.12%
Previous 0.12%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$47.98 - $54.4 $8,492 - $9,628
-177 Reduced 1.21%
14,441 $783,000
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $68,114 - $81,279
1,405 Added 10.63%
14,618 $750,000
Q3 2023

Oct 20, 2023

SELL
$57.89 - $64.73 $59,626 - $66,671
-1,030 Reduced 7.23%
13,213 $766,000
Q2 2023

Aug 09, 2023

SELL
$63.71 - $70.74 $36,378 - $40,392
-571 Reduced 3.85%
14,243 $910,000
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $7,030 - $7,974
107 Added 0.73%
14,814 $1.03 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $28,145 - $33,327
-411 Reduced 2.72%
14,707 $1.06 Million
Q3 2022

Nov 07, 2022

SELL
$0.13 - $76.84 $47 - $27,969
-364 Reduced 2.35%
15,118 $1.08 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $34,784 - $38,310
-479 Reduced 3.0%
15,482 $1.2 Million
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $193,662 - $232,218
-3,150 Reduced 16.48%
15,961 $1.17 Million
Q4 2021

Feb 04, 2022

SELL
$53.63 - $62.52 $74,223 - $86,527
-1,384 Reduced 6.75%
19,111 $1.19 Million
Q3 2021

Nov 02, 2021

BUY
$59.17 - $69.31 $2,189 - $2,564
37 Added 0.18%
20,495 $1.21 Million
Q2 2021

Jul 21, 2021

BUY
$61.91 - $67.42 $26,497 - $28,855
428 Added 2.14%
20,458 $1.37 Million
Q1 2021

May 13, 2021

SELL
$59.34 - $66.74 $230,773 - $259,551
-3,889 Reduced 16.26%
20,030 $1.27 Million
Q4 2020

Feb 04, 2021

BUY
$57.74 - $65.43 $11,317 - $12,824
196 Added 0.83%
23,919 $1.47 Million
Q3 2020

Nov 05, 2020

SELL
$57.43 - $63.64 $34,458 - $38,184
-600 Reduced 2.47%
23,723 $1.41 Million
Q2 2020

Jul 30, 2020

SELL
$54.82 - $64.09 $14,253 - $16,663
-260 Reduced 1.06%
24,323 $1.44 Million
Q1 2020

May 08, 2020

BUY
$46.4 - $67.43 $1.14 Million - $1.66 Million
24,583 New
24,583 $1.37 Million
Q4 2019

Feb 07, 2020

SELL
$49.21 - $64.19 $1.33 Million - $1.74 Million
-27,113 Closed
0 $0
Q3 2019

Nov 07, 2019

BUY
$42.77 - $50.71 $100,167 - $118,762
2,342 Added 9.45%
27,113 $1.39 Million
Q2 2019

Jul 25, 2019

BUY
$44.62 - $49.34 $39,265 - $43,419
880 Added 3.68%
24,771 $1.12 Million
Q1 2019

May 10, 2019

SELL
$45.12 - $53.8 $820,913 - $978,837
-18,194 Reduced 43.23%
23,891 $1.14 Million
Q4 2018

Jan 31, 2019

SELL
$48.76 - $63.23 $209,716 - $271,952
-4,301 Reduced 9.27%
42,085 $2.19 Million
Q3 2018

Nov 09, 2018

BUY
$55.19 - $62.25 $2,207 - $2,490
40 Added 0.09%
46,386 $2.39 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $2.34 Million - $2.92 Million
46,346 New
46,346 $2.58 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $2.63 Million - $3.03 Million
-43,864 Closed
0 $0
Q4 2017

Feb 13, 2018

SELL
$59.94 - $65.35 $1,198 - $1,307
-20 Reduced 0.05%
43,864 $2.69 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $58,930 - $68,010
1,067 Added 2.49%
43,884 $2.8 Million
Q2 2017

Aug 16, 2017

BUY
N/A
42,817
42,817 $2.39 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $86B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hcr Wealth Advisors Portfolio

Follow Hcr Wealth Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hcr Wealth Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Hcr Wealth Advisors with notifications on news.